Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 255.38
NLNK's Cash-to-Debt is ranked higher than
55% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NLNK: 255.38 )
Ranked among companies with meaningful Cash-to-Debt only.
NLNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79  Med: 53.72 Max: N/A
Current: 255.38
Equity-to-Asset 0.76
NLNK's Equity-to-Asset is ranked higher than
61% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NLNK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
NLNK' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.78 Max: 0.93
Current: 0.76
-5.11
0.93
Piotroski F-Score: 3
Altman Z-Score: 1.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -263.74
NLNK's Operating Margin % is ranked lower than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NLNK: -263.74 )
Ranked among companies with meaningful Operating Margin % only.
NLNK' s Operating Margin % Range Over the Past 10 Years
Min: -2849.13  Med: -964.85 Max: 68.12
Current: -263.74
-2849.13
68.12
Net Margin % -250.90
NLNK's Net Margin % is ranked lower than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NLNK: -250.90 )
Ranked among companies with meaningful Net Margin % only.
NLNK' s Net Margin % Range Over the Past 10 Years
Min: -2852.7  Med: -966.19 Max: 55.63
Current: -250.9
-2852.7
55.63
ROE % -58.13
NLNK's ROE % is ranked lower than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NLNK: -58.13 )
Ranked among companies with meaningful ROE % only.
NLNK' s ROE % Range Over the Past 10 Years
Min: -85.27  Med: -52.36 Max: 75.23
Current: -58.13
-85.27
75.23
ROA % -46.26
NLNK's ROA % is ranked lower than
62% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NLNK: -46.26 )
Ranked among companies with meaningful ROA % only.
NLNK' s ROA % Range Over the Past 10 Years
Min: -86.63  Med: -59.94 Max: 63.63
Current: -46.26
-86.63
63.63
ROC (Joel Greenblatt) % -1122.52
NLNK's ROC (Joel Greenblatt) % is ranked lower than
63% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NLNK: -1122.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NLNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1122.52  Med: -386.28 Max: 1042.38
Current: -1122.52
-1122.52
1042.38
3-Year Revenue Growth Rate 206.20
NLNK's 3-Year Revenue Growth Rate is ranked higher than
99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NLNK: 206.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NLNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 64.15 Max: 209.3
Current: 206.2
0
209.3
3-Year EBITDA Growth Rate 34.70
NLNK's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NLNK: 34.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NLNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: 34.7
Current: 34.7
0
34.7
3-Year EPS without NRI Growth Rate 33.70
NLNK's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NLNK: 33.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NLNK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.3 Max: 33.7
Current: 33.7
0
33.7
GuruFocus has detected 3 Warning Signs with NewLink Genetics Corp $NLNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NLNK's 30-Y Financials

Financials (Next Earnings Date: 2017-07-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

NLNK Guru Trades in Q2 2016

Paul Tudor Jones 35,400 sh (+96.67%)
First Eagle Investment 2,186,700 sh (+24.62%)
Jim Simons 815,500 sh (+12.22%)
First Eagle Investment 5,913 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q3 2016

NLNK Guru Trades in Q3 2016

First Eagle Investment 5,713 sh (unchged)
First Eagle Investment 2,186,700 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 346,800 sh (-57.47%)
» More
Q4 2016

NLNK Guru Trades in Q4 2016

First Eagle Investment 5,713 sh (unchged)
First Eagle Investment 2,129,200 sh (-2.63%)
Jim Simons 145,800 sh (-57.96%)
» More
Q1 2017

NLNK Guru Trades in Q1 2017

Joel Greenblatt 12,976 sh (New)
Steven Cohen 40,000 sh (New)
Charles Brandes 9,173 sh (New)
First Eagle Investment 2,299,200 sh (+7.98%)
First Eagle Investment 3,690 sh (unchged)
Jim Simons 47,900 sh (-67.15%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AVXL, NAS:CEMP, NAS:OVID, NAS:CKPT, NAS:PTGX, NAS:FBIO, NAS:CASC, NAS:ALBO, NAS:XBIT, NAS:CNAT, OTCPK:TYMI, NAS:PPHM, NAS:KURA, NAS:SBBP, TSX:VBV, NAS:CLSD, NAS:CERS, NAS:IMDZ, NAS:CMRX, NAS:MDGL » details
Traded in other countries:4NX.Germany,
Headquarter Location:USA
NewLink Genetics Corp is a clinical stage immuno-oncology company based in US. It focuses on developing novel immunotherapeutic products for the treatment of cancer. Its portfolio contains biologic and small-molecule immuno-oncology product candidates.

NewLink Genetics is an American biotechnology company targeting immunotherapeutic products to improve treatment options for patients with cancer. The company's portfolio contains biologic and small-molecule immuno-oncology product candidates intended to treat a wide variety of oncology indications. Its products are based on the proprietary HyperAcute Cellular Immunotherapy technology, which is expected to stimulate the human immune system.

Top Ranked Articles about NewLink Genetics Corp

NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid,
NewLink Genetics to Regain Rights to GDC-0919
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
NewLink Genetics to Participate in Upcoming Investor Conferences
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp
NewLink Genetics Announces Presentation of Two Abstracts at ASCO
NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017
Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary

Ratios

vs
industry
vs
history
PB Ratio 1.87
NLNK's PB Ratio is ranked higher than
77% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NLNK: 1.87 )
Ranked among companies with meaningful PB Ratio only.
NLNK' s PB Ratio Range Over the Past 10 Years
Min: 1.56  Med: 6.15 Max: 21.18
Current: 1.87
1.56
21.18
PS Ratio 6.42
NLNK's PS Ratio is ranked higher than
64% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. NLNK: 6.42 )
Ranked among companies with meaningful PS Ratio only.
NLNK' s PS Ratio Range Over the Past 10 Years
Min: 5.42  Med: 61.67 Max: 1081.4
Current: 6.42
5.42
1081.4
EV-to-EBIT -1.14
NLNK's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NLNK: -1.14 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.9  Med: -8.85 Max: 13.5
Current: -1.14
-36.9
13.5
EV-to-EBITDA -1.21
NLNK's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NLNK: -1.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
NLNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38  Med: -9.15 Max: 13.4
Current: -1.21
-38
13.4
Current Ratio 5.12
NLNK's Current Ratio is ranked higher than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NLNK: 5.12 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.59 Max: 25.95
Current: 5.12
0.97
25.95
Quick Ratio 5.12
NLNK's Quick Ratio is ranked higher than
59% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NLNK: 5.12 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.59 Max: 25.95
Current: 5.12
0.97
25.95
Days Sales Outstanding 177.18
NLNK's Days Sales Outstanding is ranked lower than
87% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. NLNK: 177.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.42  Med: 159.67 Max: 617.06
Current: 177.18
26.42
617.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
NLNK's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NLNK: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NLNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -6.95 Max: 0
Current: -3.1
-23.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.56
NLNK's Price-to-Net-Cash is ranked higher than
82% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. NLNK: 2.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NLNK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.49  Med: 8.44 Max: 29.76
Current: 2.56
2.49
29.76
Price-to-Net-Current-Asset-Value 1.97
NLNK's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. NLNK: 1.97 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NLNK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.92  Med: 6.73 Max: 21.93
Current: 1.97
1.92
21.93
Price-to-Tangible-Book 1.86
NLNK's Price-to-Tangible-Book is ranked higher than
82% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NLNK: 1.86 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NLNK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.81  Med: 5.96 Max: 14.64
Current: 1.86
1.81
14.64
Price-to-Median-PS-Value 0.10
NLNK's Price-to-Median-PS-Value is ranked higher than
97% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NLNK: 0.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NLNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.26 Max: 10.97
Current: 0.1
0.09
10.97
Earnings Yield (Greenblatt) % -91.03
NLNK's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NLNK: -91.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NLNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -141.4  Med: -7.55 Max: 16.7
Current: -91.03
-141.4
16.7

More Statistics

Revenue (TTM) (Mil) $32.82
EPS (TTM) $ -2.84
Beta2.32
Short Percentage of Float12.78%
52-Week Range $5.90 - 25.17
Shares Outstanding (Mil)29.23

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -2.53 -2.30
EPS without NRI ($) -2.53 -2.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:NLNK

Headlines

Articles On GuruFocus.com
NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs Jul 10 2017 
Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination w Jun 23 2017 
NewLink Genetics to Regain Rights to GDC-0919 Jun 08 2017 
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cance Jun 02 2017 
NewLink Genetics to Participate in Upcoming Investor Conferences May 08 2017 
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance May 04 2017 
Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharm May 03 2017 
NewLink Genetics Announces Presentation of Two Abstracts at ASCO Apr 21 2017 
NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017 Apr 13 2017 
Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda Apr 04 2017 

More From Other Websites
ETFs with exposure to NewLink Genetics Corp. : July 12, 2017 Jul 12 2017
NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs Jul 10 2017
NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017 Jul 07 2017
Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with... Jun 23 2017
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Jun 21 2017
A Surprising Disappointment Derails NewLink Genetics -- What's Next? Jun 19 2017
Are Options Traders Betting on a Big Move in NewLink (NLNK) Stock? Jun 13 2017
Roche-NewLink Drug Move Shouldn't Impact Incyte, Says Analyst Jun 09 2017
Why Sina, Eldorado Gold, and NewLink Genetics Slumped Today Jun 08 2017
Stocks Pull Off Narrow Win, But These Four Soared To New Highs Jun 08 2017
Why Is NewLink Genetics Losing One-Third of Its Value Today? Jun 08 2017
NewLink Genetics Sinks After Regaining Licensing Rights for Its Cancer Treatment Jun 08 2017
Biotech Movers: NewLink, Inovio, Juno Jun 08 2017
NewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate Jun 08 2017
NewLink Genetics to Regain Rights to GDC-0919 Jun 08 2017
Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today Jun 05 2017
Biotech Movers: Loxo, NewLink, BioCryst Jun 05 2017
NewLink Genetics’ Indoximod + PROVENGE® Results in Statistically Significant Improvement in... Jun 05 2017
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast... Jun 02 2017
Cancer drug prices could double or triple thanks to this popular but unproven drug trend Jun 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}